ラニビズマブの世界市場レポート 2024年

ラニビズマブの市場規模は、今後数年間で安定した成長が見込まれます。2028年には年間平均成長率（CAGR）4.4％で31億6,000万米ドルに成長します。予測期間の成長は、継続的な研究開発努力、バイオシミラーの採用、併用療法への注目の高まり、遠隔眼科医療の拡大、ラニビズマブの適応拡大、有利な償還政策などに起因すると考えられます。この期間に予想される主要動向としては、バイオテクノロジーの進歩、ドラッグデリバリーシステムの技術的改善、個別化医療への動き、眼科領域における人工知能の利用拡大、長時間作用型製剤の開発、患者中心のケアモデルの増加などが挙げられます。

眼疾患の発生は増加しており、将来的にラニビズマブ市場の拡大を牽引するものと考えられます。眼疾患は、視力や目の健康に影響を及ぼす様々な症状を包含し、高齢化、ライフスタイルの変化、糖尿病などの慢性疾患の増加などの要因がその蔓延に寄与しています。ラニビズマブは加齢黄斑変性症や糖尿病性網膜症などの治療に使用され、眼疾患の有病率が高まる中、視力障害の軽減に一役買っています。例えば、国際失明予防機関（IAPB）は、2050年までに視力損失が55％増加し、罹患者数は2020年の11億600万人から2050年には17億5,800万人に増加すると予測しています。したがって、眼疾患の発生が増加していることは、ラニビズマブ市場の成長を促進すると考えられます。

ラニビズマブ市場の主要参入企業は、網膜疾患患者の視力低下に対処し、それを予防するために、ラニビズマブのバイオシミラーなど、費用対効果の高い治療法の開拓に注力しています。ラニビズマブのバイオシミラーとは、オリジナルのラニビズマブと非常に類似しているが、別のブランド名で販売されている生物製剤を指し、同等の有効性と安全性プロファイルを維持しながら、より経済的な代替品を記載しています。例えば、Formycon AGとBioeq AGは、ルセンティス（ラニビズマブ）のバイオシミラーであるFYB201を2024年4月にカナダとスイスで発売すると発表しました。RanoptoとRanivisioという商品名で、それぞれカナダ保健省とSwissmedicから販売許可を得て発売されるこの製品は、重篤な網膜疾患に対する有効で手ごろな価格の新たな治療選択肢を記載しています。すでに米国や欧州各地の患者にとって費用対効果の高い治療選択肢であることが証明されています。

目次

第1章 エグゼクティブ概要

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界の市場規模と成長

• 世界のラニビズマブ市場：促進要因と抑制要因
  • 市場促進要因
  • 市場抑制要因
• 世界のラニビズマブ市場の実績：規模と成長、2018～2023年
• 世界のラニビズマブ市場の予測：規模と成長、2023～2028年、2033年

第6章 市場セグメンテーション

• 世界のラニビズマブ市場：製品別、実績と予測、2018～2023年、2023～2028年、2033年
• 使い捨てプレフィルドシリンジ
• 使い捨てガラスバイアル
• 世界のラニビズマブ市場：用途別、実績と予測、2018～2023年、2023～2028年、2033年
• 滲出型加齢黄斑変性症（AMD）
• 糖尿病網膜症（DR）
• 糖尿病黄斑浮腫（DME）
• 近視性脈絡膜新生血管（MCNV）
• 網膜静脈閉塞症（RVO）
• 世界のラニビズマブ市場：流通チャネル別、実績と予測、2018～2023年、2023～2028年、2033年
• 病院薬局
• オンライン薬局
• その他

第7章 地域別・国別分析

• 世界のラニビズマブ市場：地域別、実績と予測、2018～2023年、2023～2028年、2033年
• 世界のラニビズマブ市場：国別、実績と予測、2018～2023年、2023～2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• ラニビズマブ市場：競合情勢
• ラニビズマブ市場：企業プロファイル
  • F. Hoffmann-La Roche AG
  • Bayer AG
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd
  • Regeneron Pharmaceuticals Inc.

第31章 その他の大手企業と革新的企業

• Biogen Inc
• Sun Pharmaceutical Industries Ltd.
• Stada Arzneimittel AG
• Genentech Inc.
• Dr Reddy's Laboratories Ltd
• Cipla Limited
• Samsung Biologics Co Ltd
• Lupin Limited
• Biocon Limited
• Celltrion Healthcare Co Ltd
• Glenmark Pharmaceuticals Limited
• Enzene Biosciences Ltd
• Coherus BioSciences Inc
• Amman Pharmaceutical Industries
• Formycon AG

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の展望と潜在的な分析

第36章 付録

Ranibizumab is a recombinant humanized monoclonal antibody fragment designed to inhibit vascular endothelial growth factor A (VEGF-A) activity in treating various retinal conditions. It works by reducing abnormal blood vessel growth and leakage in the eye. Its advantage lies in targeted delivery via intravitreal injection, minimizing systemic side effects while preserving and potentially improving vision.

The main types of ranibizumab include single-use prefilled syringes and single-use glass vials. Single-use ranibizumab syringes are intended for one-time use, filled with the appropriate dosage before distribution, and disposed of after a single injection. They are used in conditions such as wet age-related macular degeneration (AMD), diabetic retinopathy (DR), diabetic macular edema (DME), myopic choroidal neovascularization (MCNV), and retinal vein occlusion (RVO). These are distributed through channels such as hospital pharmacies, online pharmacies, and others.

The ranibizumab market research report is one of a series of new reports from the business research company that provides ranibizumab market statistics, including ranibizumab industry global market size, regional shares, competitors with an ranibizumab market share, detailed ranibizumab market segments, market trends and opportunities, and any further data you may need to thrive in the ranibizumab industry. This ranibizumab market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The ranibizumab market size has grown steadily in recent years. It will grow from $2.55 billion in 2023 to $2.66 billion in 2024 at a compound annual growth rate (CAGR) of 4.3%. The growth in the historic period can be attributed to several factors, including the expansion of clinical trials in emerging markets, the increasing prevalence of age-related macular degeneration (AMD), growing awareness about retinal diseases, the high incidence of diabetic retinopathy, government initiatives and funding, and rising healthcare expenditure.

The ranibizumab market size is expected to see steady growth in the next few years. It will grow to $3.16 billion in 2028 at a compound annual growth rate (CAGR) of 4.4%. The growth in the forecast period can be attributed to ongoing research and development efforts, the introduction of biosimilars, a growing focus on combination therapies, the expansion of teleophthalmology, widening indications for ranibizumab, and favorable reimbursement policies. Major trends expected during this period include advancements in biotechnology, technological improvements in drug delivery systems, a move towards personalized medicine, increased use of artificial intelligence in ophthalmology, development of longer-acting formulations, and an increase in patient-centric care models.

The increasing occurrence of eye diseases is poised to drive the expansion of the ranibizumab market in the future. Eye diseases encompass various conditions affecting vision and eye health, with factors such as aging populations, lifestyle changes, and the rise in chronic conditions such as diabetes contributing to their prevalence. Ranibizumab is utilized in treating conditions such as age-related macular degeneration and diabetic retinopathy, playing a role in reducing vision impairment amidst the growing prevalence of eye diseases. For example, the International Agency for the Prevention of Blindness (IAPB) projected a 55% increase in vision loss by 2050, with the number of affected individuals expected to rise from 1,106 million in 2020 to 1,758 million in 2050. Hence, the increasing occurrence of eye diseases will fuel the growth of the ranibizumab market.

Key players in the ranibizumab market are focusing on developing cost-effective therapies, such as biosimilars of ranibizumab, to address and prevent vision loss in patients with retinal disorders. A biosimilar of ranibizumab refers to a biologic medication highly similar to the original ranibizumab but marketed under a different brand name, providing a more economical alternative while maintaining comparable efficacy and safety profiles. For instance, Formycon AG and Bioeq AG announced the commercial release of FYB201, a biosimilar to Lucentis (Ranibizumab), in Canada and Switzerland in April 2024. This launch, under the brand names Ranopto and Ranivisio, following marketing authorization from Health Canada and Swissmedic respectively, offers a new, effective, and affordable treatment option for severe retinal diseases. It has already proven to be a cost-effective treatment choice for patients in the USA and various parts of Europe.

In March 2024, Sandoz Group AG acquired the CIMERLI business from Coherus BioSciences to bolster its position in the biosimilar market, particularly in ophthalmology. This move leverages Coherus BioSciences' expertise in developing biosimilar versions of medications such as Ranibizumab, used in treating eye diseases. Coherus BioSciences, a US-based biopharmaceutical company, focuses on developing biosimilar versions of medications such as Ranibizumab.

Major companies operating in the ranibizumab market are F. Hoffmann-La Roche AG, Bayer AG, Novartis AG, Teva Pharmaceutical Industries Ltd, Regeneron Pharmaceuticals Inc., Biogen Inc, Sun Pharmaceutical Industries Ltd., Stada Arzneimittel AG, Genentech Inc., Dr Reddy's Laboratories Ltd, Cipla Limited, Samsung Biologics Co Ltd, Lupin Limited, Biocon Limited, Celltrion Healthcare Co Ltd, Glenmark Pharmaceuticals Limited, Enzene Biosciences Ltd, Coherus BioSciences Inc, Amman Pharmaceutical Industries , Formycon AG, Intas Pharmaceuticals Ltd, Alvotech, Xbrane Biopharma AB

North America was the largest region in the ranibizumab market in 2023 The regions covered in the ranibizumab market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the ranibizumab market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The ranibizumab market consists of sales of biosimilars, intravitreal injections, and compounded formulations. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Ranibizumab Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on ranibizumab market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for ranibizumab ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The ranibizumab market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of COVID-19 on supply chains and consumption patterns.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product: Single Use Prefilled Syringe; Single Use Glass Vial
• 2) By Application: Wet Age Related Macular Degeneration (AMD); Diabetic Retinopathy (DR); Diabetic Macular Edema (DME); Myopic Choroidal Neovascularization (MCNV); Retinal Vein Occlusion (RVO)
• 3) By Distribution Channel: Hospital Pharmacies; Online Pharmacies; Other Distribution Channels
• Companies Mentioned: F. Hoffmann-La Roche AG; Bayer AG; Novartis AG; Teva Pharmaceutical Industries Ltd; Regeneron Pharmaceuticals Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Ranibizumab Market Characteristics

3. Ranibizumab Market Trends And Strategies

4. Ranibizumab Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On The Market
• 4.2. Ukraine-Russia War Impact On The Market
• 4.3. COVID-19 Impact On The Market

5. Global Ranibizumab Market Size and Growth

• 5.1. Global Ranibizumab Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Ranibizumab Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Ranibizumab Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Ranibizumab Market Segmentation

• 6.1. Global Ranibizumab Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Single Use Prefilled Syringe
• Single Use Glass Vial
• 6.2. Global Ranibizumab Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Wet Age Related Macular Degeneration (AMD)
• Diabetic Retinopathy (DR)
• Diabetic Macular Edema (DME)
• Myopic Choroidal Neovascularization (MCNV)
• Retinal Vein Occlusion (RVO)
• 6.3. Global Ranibizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospital Pharmacies
• Online Pharmacies
• Other Distribution Channels

7. Ranibizumab Market Regional And Country Analysis

• 7.1. Global Ranibizumab Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Ranibizumab Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Ranibizumab Market

• 8.1. Asia-Pacific Ranibizumab Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Ranibizumab Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Ranibizumab Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Ranibizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Ranibizumab Market

• 9.1. China Ranibizumab Market Overview
• 9.2. China Ranibizumab Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Ranibizumab Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Ranibizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Ranibizumab Market

• 10.1. India Ranibizumab Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Ranibizumab Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Ranibizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Ranibizumab Market

• 11.1. Japan Ranibizumab Market Overview
• 11.2. Japan Ranibizumab Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Ranibizumab Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Ranibizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Ranibizumab Market

• 12.1. Australia Ranibizumab Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Ranibizumab Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Ranibizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Ranibizumab Market

• 13.1. Indonesia Ranibizumab Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Ranibizumab Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Ranibizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Ranibizumab Market

• 14.1. South Korea Ranibizumab Market Overview
• 14.2. South Korea Ranibizumab Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Ranibizumab Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Ranibizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Ranibizumab Market

• 15.1. Western Europe Ranibizumab Market Overview
• 15.2. Western Europe Ranibizumab Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Ranibizumab Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Ranibizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Ranibizumab Market

• 16.1. UK Ranibizumab Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Ranibizumab Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Ranibizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Ranibizumab Market

• 17.1. Germany Ranibizumab Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Ranibizumab Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Ranibizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Ranibizumab Market

• 18.1. France Ranibizumab Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France Ranibizumab Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France Ranibizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Ranibizumab Market

• 19.1. Italy Ranibizumab Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy Ranibizumab Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy Ranibizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Ranibizumab Market

• 20.1. Spain Ranibizumab Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain Ranibizumab Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain Ranibizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Ranibizumab Market

• 21.1. Eastern Europe Ranibizumab Market Overview
• 21.2. Eastern Europe Ranibizumab Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Ranibizumab Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Ranibizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Ranibizumab Market

• 22.1. Russia Ranibizumab Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Ranibizumab Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Ranibizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Ranibizumab Market

• 23.1. North America Ranibizumab Market Overview
• 23.2. North America Ranibizumab Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Ranibizumab Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Ranibizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Ranibizumab Market

• 24.1. USA Ranibizumab Market Overview
• 24.2. USA Ranibizumab Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Ranibizumab Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Ranibizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Ranibizumab Market

• 25.1. Canada Ranibizumab Market Overview
• 25.2. Canada Ranibizumab Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Ranibizumab Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Ranibizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Ranibizumab Market

• 26.1. South America Ranibizumab Market Overview
• 26.2. South America Ranibizumab Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Ranibizumab Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Ranibizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Ranibizumab Market

• 27.1. Brazil Ranibizumab Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Ranibizumab Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Ranibizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Ranibizumab Market

• 28.1. Middle East Ranibizumab Market Overview
• 28.2. Middle East Ranibizumab Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Ranibizumab Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Ranibizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Ranibizumab Market

• 29.1. Africa Ranibizumab Market Overview
• 29.2. Africa Ranibizumab Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Ranibizumab Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Ranibizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Ranibizumab Market Competitive Landscape And Company Profiles

• 30.1. Ranibizumab Market Competitive Landscape
• 30.2. Ranibizumab Market Company Profiles
  • 30.2.1. F. Hoffmann-La Roche AG
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. Bayer AG
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. Novartis AG
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. Teva Pharmaceutical Industries Ltd
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. Regeneron Pharmaceuticals Inc.
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Ranibizumab Market Other Major And Innovative Companies

• 31.1. Biogen Inc
• 31.2. Sun Pharmaceutical Industries Ltd.
• 31.3. Stada Arzneimittel AG
• 31.4. Genentech Inc.
• 31.5. Dr Reddy's Laboratories Ltd
• 31.6. Cipla Limited
• 31.7. Samsung Biologics Co Ltd
• 31.8. Lupin Limited
• 31.9. Biocon Limited
• 31.10. Celltrion Healthcare Co Ltd
• 31.11. Glenmark Pharmaceuticals Limited
• 31.12. Enzene Biosciences Ltd
• 31.13. Coherus BioSciences Inc
• 31.14. Amman Pharmaceutical Industries
• 31.15. Formycon AG

32. Global Ranibizumab Market Competitive Benchmarking

33. Global Ranibizumab Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Ranibizumab Market

35. Ranibizumab Market Future Outlook and Potential Analysis

• 35.1 Ranibizumab Market In 2028 - Countries Offering Most New Opportunities
• 35.2 Ranibizumab Market In 2028 - Segments Offering Most New Opportunities
• 35.3 Ranibizumab Market In 2028 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer